Amphion Innovations plc
London and New York, 1 May 2009 – Amphion Innovations plc (LSE: AMP), the developer of medical and technology businesses, today announces the appointment of Mr. Gerard Moufflet as Non-executive Director with immediate effect.
Mr. Moufflet, aged 65, is Chief Executive Officer and founder of Acceleration International, a private equity firm based in Boston, which invests in the healthcare sector in both Europe and the US. From 1989 to 2001, Mr. Moufflet was a Managing Director at Advent International, one of the world's leading private equity firms where he was in charge of the Healthcare Practice on a worldwide basis. From 1972 to 1989 Mr. Moufflet worked for Baxter International where he was in charge of various European and African operations and Head of Worldwide Strategic Planning for the dialysis product line. When he became Corporate Vice President and Vice President of Baxter World Trade, Baxter had grown to $7 billion in sales.
Mr. Moufflet currently serves on the Board of NASDAQ listed American Dental Partners, The Natural Dentist, Kika Medical, Spinelab, Thommen Medical AG, Ranir LLC, BarrierSafe Solutions International, and Amphion Partner Company, Motif BioSciences, Inc. He is also Chairman of the Board of Fellows of The Harvard Dental School of Medicine. Mr. Moufflet was formally on the Board of Critical Care Systems (now Medco), Serologicals (now Millipore), and Brontes (now 3M).
Commenting on the appointment Chief Executive Officer, Richard Morgan, said, “We are delighted to welcome Mr. Moufflet to the Amphion Board. We are confident that he will be a key addition to the company with his wide range of experience and expertise.”
The Company also announces that Mr. Ronald Thomas, Non-executive Director, has decided not to stand for re-election at the Company’s Annual General Meeting on 4 June 2009 and will therefore retire from the Board on that date. The Board would like to take this opportunity to thank Mr. Thomas for his valued contribution and wish him well for the future.
Save as disclosed above, there are no further details required to be disclosed pursuant to schedule 2(g) of the AIM rules.
For further information please contact
Amphion Innovations plc
Charlie Morgan, Director of Communications
+1 (212) 210 6224
Tim Robertson/ Jamie Milton/ Matthew Law
+44 20 7930 0777
Charles Stanley (Nominated Adviser)
Mark Taylor/ Freddy Crossley
+44 20 7149 6000
About Amphion Innovations plc
Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has a significant shareholding in ten Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.
On the web: www.amphionplc.com